Loading...
Loading...
Dataset URI:
10.6084/m9.figshare.32286943.v1Fatigue is a disabling symptom of multiple sclerosis (MS) with an unknown etiology. Various medications are used to treat MS-related fatigue, but none of the available studies directly compared the head-to-head efficacy of all these medications. So, we designed this meta-analysis to compare the efficacy of these drugs in treating MS-related fatigue. PubMed, Scopus, EMBASE, PsycINFO, and Web of Science were thoroughly searched by two independent researchers on 1 March 2025. Mean difference (SMD) was used as the effect size, and surface under the cumulative ranking curve (SUCRA) was applied to rank interventions. 15 studies were ultimately included in the systematic review. For fatigue severity, none of the medications were superior to placebo. For fatigue impact (MFIS) compared with placebo, Amantadine (MD −12.11, 95% CI −14.28 to −9.94), Dalfampridine (MD −14.05, 95% CI −22.59 to −5.52, and Methylphenidate (MD −5.25, 95% CI −8.44 to −2.06) were associated with statistically significant improvements. In contrast, CBT (MD 1.40, 95% CI −1.99 to 4.80), and Modafinil (MD 0.60, 95% CI −1.26 to 2.46) did not differ significantly from placebo. Amantadine, dalfampridine, and methylphenidate were found to be superior to placebo in improving the impact of fatigue on patients’ lives.
Keyword(s):
Biological Sciences not elsewhere classified; fatigue; Immunology; Medicine; meta-analysis.
MeSH Term(s):
Grants and Funding:
Associated Publication(s):
Supplementary Data:
No Supplementary Data Available
Related Dataset(s):
No Related Dataset Data Available
The National Library of Medicine (NLM) provides information about biomedical datasets. Inclusion on an NLM Web page does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. Learn more: NLM Web Policies (nih.gov)